Anavex Life Sciences Corp (AVXL)

[Guzzi62]

No, I am aware that the peer review don't give automatically approval, but for me, it's the DD it provides. I believe in the journal, but not so much self-proclaimed experts posting on a message board.

Role of the 58 authors: I heard that the first name on the list is the main author and the last name on the list is the 2nd most important person writing the journal, but I haven't got that 100% confirmed!

So in our case, the main persons are, if above is true:

Stephen Macfarlane
The Dementia Centre, HammondCare, Melbourne, Victoria, Australia

Marwan N Sabbagh
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
Corresponding author at: Barrow Neurological Institute, St. Joseph's Hospital and Medical Center 240 W. Thomas Rd.; Phoenix, AZ 85013, USA.

My layman conclusion is that we will get approval with EMA because there isn't anything they want (EMA) out there and Leqembi is only for a very small group not likely getting brain bleed.
"Docs" conclusion at 4% likelihood is just plain space cadet IMO.
Phase 4? Yes, likely, but that's fine, isn't it?